Noninvasive Detection of Extracellular pH in Human Benign and Malignant Liver Tumors Using CEST MRI
In this study, we aimed to use 3T magnetic resonance imaging (MRI), which is clinically available, to determine the extracellular pH (pHe) of liver tumors and prospectively evaluate the ability of chemical exchange saturation transfer (CEST) MRI to distinguish between benign and malignant liver tumo...
Saved in:
Published in | Frontiers in oncology Vol. 10; p. 578985 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
02.11.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | In this study, we aimed to use 3T magnetic resonance imaging (MRI), which is clinically available, to determine the extracellular pH (pHe) of liver tumors and prospectively evaluate the ability of chemical exchange saturation transfer (CEST) MRI to distinguish between benign and malignant liver tumors.
Different radiofrequency irradiation schemes were assessed for ioversol-based pH measurements at 3T. CEST effects were quantified
using the asymmetric magnetization transfer ratio (MTRasym) at 4.3 ppm from the corrected Z spectrum. Generalized ratiometric analysis was conducted by rationing resolved ioversol CEST effects at 4.3 ppm at a flip angle of 60 and 350°. Fifteen patients recently diagnosed with hepatic carcinoma and five patients diagnosed with hepatic hemangioma [1 male; mean age, 48.6 (range, 37-59) years] were assessed.
By conducting dual-power CEST MRI, the pH of solutions was determined to be 6.0-7.2 at 3T
. In vivo, ioversol signal intensities in the tumor region showed that the extracellular pH in hepatic carcinoma was acidic(mean ± standard deviation, 6.66 ± 0.19), whereas the extracellular pH was more physiologically neutral in hemangioma (mean ± standard deviation, 7.34 ± 0.09).The lesion size was similar between CEST pH MRI and T2-weighted imaging.
dual-power CEST MRI can detect extracellular pH in human liver tumors and can provide molecular-level diagnostic tools for differentiating benign and malignant liver tumors at 3T. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Cancer Imaging and Image-directed Interventions, a section of the journal Frontiers in Oncology Edited by: Sebastian Cerdan, Consejo Superior de Investigaciones Científicas (CSIC), Spain Reviewed by: Mark D. Pagel, University of Texas MD Anderson Cancer Center, United States; Guanshu Liu, Johns Hopkins University, United States; Zhongliang Zu, Vanderbilt University, United States |
ISSN: | 2234-943X 2234-943X |
DOI: | 10.3389/fonc.2020.578985 |